Shabir Madhi

Last updated

Shabir Ahmed Madhi
Shabir Madhi for Fundacion Civio.jpg
Madhi in 2017
Born1966 (age 5657)
NationalitySouth African
Education University of the Witwatersrand, Johannesburg
Known forLeading COVID-19 vaccine trials in South Africa
Medical career
ProfessionPhysician
Sub-specialties Vaccinology

Shabir Ahmed Madhi (born 1966) is a South African physician who is professor of vaccinology and director of the South African Medical Research Council Respiratory and Meningeal Pathogens Research Unit at the University of the Witwatersrand, and National Research Foundation/Department of Science and Technology Research Chair in Vaccine Preventable Diseases. In January 2021, he was appointed Dean of the Faculty of Health Sciences at the University of the Witwateratand.

Contents

He was executive director of South Africa's National Institute for Communicable Diseases from 2011 to 2017, and has served on several WHO committees in roles pertinent to vaccines and pneumonia. In 2018, he co-founded the African Leadership in Vaccinology Expertise (ALIVE) and was appointed Chair of South Africa's National Advisory Group on Immunization (NAGI).

His research has included studies on the pneumococcal conjugate vaccine and rotavirus vaccine, and in pregnant women, the influenza and respiratory syncytial virus vaccines.

Since the global COVID-19 pandemic in 2020, he has been leading COVID-19 vaccine trials in South Africa, including the first in Africa. In 2021 he stated that the first and foremost method of ending COVID-19 in South Africa is to implement a mass vaccination programme.

Early life and education

Madhi was born in 1966. [1] His father was a teacher and mother a housewife. [2] Initially aspiring to becoming an engineer, he opted to accept a bursary to study medicine and was initially reluctant to persist with his medical education. [2] In 1990 he completed his undergraduate and postgraduate training at the University of the Witwatersrand, Johannesburg, and six years later, became a fellow of the College of Paediatrics (FCPaeds (SA)). [3] During this time, with encouragement from Glenda Gray, he applied for a post under professor Keith Klugman, to work on vaccines for pneumonia. [2]

In 1998 he received a master's degree in medicine (paediatrics). [1] He gained his PhD in 2003. [1] [3]

Career

Madhi is professor of vaccinology and director of the South African Medical Research Council Respiratory and Meningeal Pathogens Research Unit at the University of the Witwatersrand, and National Research Foundation/Department of Science and Technology Research Chair in Vaccine Preventable Diseases. [3] [4] [5] These units have been rebranded as the MRC Vaccines and Infectious Diseases Analytics Research Unit (VIDA). [6]

He was executive director of South Africa's National Institute for Communicable Diseases from 2011 to 2017, and has served on several WHO committees in roles pertinent to vaccines and pneumonia. [3] In 2018, after spending four years as deputy-chair of South Africa's National Advisory Group on Immunization (NAGI), he became its chairperson. [3] In the same year he co-founded the African Leadership in Vaccinology Expertise (ALIVE), based at the University of the Witwatersrand, with the aim of expanding expertise in vaccinology in Africa. [3] In January 2021, he became Dean of the Faculty of Health Sciences of the University of the Witwateratand. [7] [8]

Pneumonia vaccine

His research has included studies on the pneumococcal conjugate vaccine. [3] [9] [10] This research led to the WHO recommendations on the delivery of this vaccine in low and middle-income countries. [3]

Rotavirus vaccine

Madhi led the first study that showed that a rotavirus vaccine could significantly prevent severe diarrhoea during the first year of life in African babies. It was published in The New England Journal of Medicine in 2010. [11] [12] The paper provided one of the key pieces of evidence for the WHO recommendations of universal rotavirus vaccination. [3]

Flu vaccine

In pregnant women, he studied the effectiveness of influenza and respiratory syncytial virus vaccines. [3] [9] [10] He led one of the largest studies evaluating the immune response to influenza vaccination in pregnant women. [13] His work showed that the risk of flu halved in women given the flu vaccine. In addition, the risk to their newborns in the first 24 weeks of life was also reduced. The findings were presented at the 16th International Congress on Infectious Diseases and he reported that his "data support the recent WHO recommendation in terms of prioritizing pregnant women for influenza vaccination, not just for the protection of the mother, but protection of the infant as well". [14] Later, he became involved in the clinical development of a vaccine against Group B streptococcus for pregnant women. [3]

Tuberculosis

Other research has involved assessing the efficacy of various drug regimens to prevent tuberculosis (TB) in people with HIV. [15]

COVID-19

Since the global COVID-19 pandemic in 2020, he has been leading COVID-19 vaccine trials in South Africa, including the Novavax COVID-19 vaccine [16] [17] and the Oxford-AstraZeneca vaccine, [18] [19] the first COVID-19 vaccine clinical trial in the continent of Africa. [20] Asserting that South Africa's second wave in December 2020 is largely driven by mass gatherings and changing people's behaviour, rather than solely on the new variant, he has called for a wider coverage of COVID-19 vaccination. [21] His co-authored publication on results of a large clinical trial of a COVID-19 vaccine suggest that the vaccine is safe and effective. [22] In 2021 he made it clear that the first and foremost method of ending COVID-19 in South Africa is to implement a mass vaccination programme. [23] On 1 January 2021 he tweeted "Ability of vaccines to impact on the pandemic is directly related to how soon you can get approx 50–60% of the population vaccinated." [23]

Awards and honours

Since 2012, he has been considered an internationally recognised scientist with an A-rating by the South Africa's National Research Foundation. [3] In 2014 he received the Platinum Medal, South African Medical Research Council's life-time award. In 2016 he received the European Developing Clinical Trial Partnership Scientific Award. [3]

Selected publications

Madhi has authored more than 350 publications between 1997 and 2018, [3] covering topics such as childhood vaccines, pneumonia, severe infections in young children and vaccination in pregnancy. [24]

Articles

Related Research Articles

<span class="mw-page-title-main">Herd immunity</span> Concept in epidemiology

Herd immunity is a form of indirect protection that applies only to contagious diseases. It occurs when a sufficient percentage of a population has become immune to an infection, whether through previous infections or vaccination, thereby reducing the likelihood of infection for individuals who lack immunity.

This is a timeline of the development of prophylactic human vaccines. Early vaccines may be listed by the first year of development or testing, but later entries usually show the year the vaccine finished trials and became available on the market. Although vaccines exist for the diseases listed below, only smallpox has been eliminated worldwide. The other vaccine-preventable illnesses continue to cause millions of deaths each year. Currently, polio and measles are the targets of active worldwide eradication campaigns.

<span class="mw-page-title-main">Pneumococcal vaccine</span> Vaccine to prevent infection by the bacteria Stretococcus pneumoniae

Pneumococcal vaccines are vaccines against the bacterium Streptococcus pneumoniae. Their use can prevent some cases of pneumonia, meningitis, and sepsis. There are two types of pneumococcal vaccines: conjugate vaccines and polysaccharide vaccines. They are given by injection either into a muscle or just under the skin.

Immunization during pregnancy is the administration of a vaccine to a pregnant individual. This may be done either to protect the individual from disease or to induce an antibody response, such that the antibodies cross the placenta and provide passive immunity to the infant after birth. In many countries, including the US, Canada, UK, Australia and New Zealand, vaccination against influenza, COVID-19 and whooping cough is routinely offered during pregnancy.

<span class="mw-page-title-main">Katherine O'Brien</span> Canadian-born pediatric physician (born 1963)

Katherine "Kate" L. O'Brien is a Canadian American pediatric infectious disease physician, epidemiologist, and vaccinologist who specializes in the areas of pneumococcal epidemiology, pneumococcal vaccine trials and impact studies, and surveillance for pneumococcal disease. She is also known as an expert in infectious diseases in American Indian populations. O’Brien is currently the Director of the World Health Organization's Department of Immunization, Vaccines and Biologicals.

<span class="mw-page-title-main">George Siber</span> Medical researcher and vaccine expert

George Rainer Siber is a medical researcher and vaccine expert with 48 years of experience in developing numerous vaccines, therapeutic antibodies, and diagnostic agents for infectious diseases.

<span class="mw-page-title-main">Helen Rees</span>

Helen Rees OBE GCOB is a medical researcher and the founder and Executive Director of the Wits Reproductive Health and HIV Institute of the University of Witwatersrand. She has led many HIV prevention and sexual and reproductive health studies and advised on vaccination strategies to help prevent various medical conditions.

Vaccine shedding is a form of viral shedding which can occur following a viral infection caused by an attenuated vaccine, which is a specific vaccine technology that uses an attenuated form of a live virus. Illness in others resulting from transmission through this type of viral shedding is rare. A large proportion of vaccines are not attenuated vaccines, and therefore cannot cause vaccine-induced viral shedding.

Kathleen Maletic Neuzil is the Director of the Center for Vaccine Development at the University of Maryland School of Medicine. She was elected to the National Academy of Medicine in 2019.

<span class="mw-page-title-main">Sarah Gilbert</span> English vaccinologist (born 1962)

Dame Sarah Catherine Gilbert FRS is an English vaccinologist who is a Professor of Vaccinology at the University of Oxford and co-founder of Vaccitech. She specialises in the development of vaccines against influenza and emerging viral pathogens. She led the development and testing of the universal flu vaccine, which underwent clinical trials in 2011.

<span class="mw-page-title-main">Arnold Monto</span> American physician and epidemiologist

Arnold Monto is an American physician and epidemiologist. At the University of Michigan School of Public Health, Monto is the Thomas Francis Jr. Collegiate Professor of Public Health, professor of epidemiology, and professor of global public health. His research focuses on the occurrence, prevention, and treatment of infectious diseases in industrialized and developing countries' populations.

<span class="mw-page-title-main">Vaccination in Brazil</span>

Vaccination in Brazil includes all the practice and social issues related to vaccines in Brazil.

Helen Aspasia Petousis-Harris is a New Zealand vaccinologist and associate professor in the Department of General Practice and Primary Health Care at the University of Auckland. She has been involved in research related to vaccination in New Zealand since 1998, with her main areas of focus being vaccine safety and effectiveness. Petousis-Harris has had a variety of lead roles in New Zealand and international organisations that focus on vaccination and is a regular media spokesperson in this field, especially during the COVID-19 pandemic.

African Leadership in Vaccinology Expertise(ALIVE), is a South African Department of Science and Technology/National Research Foundation Flagship Initiative at the University of Witwatersrand, Johannesburg, established in 2016. It was co-founded by professor of vaccinology Shabir Madhi and runs an 18-month Master of Science in Medicine in the field of Vaccinology. Its members have been contributing to COVID-19 vaccine trials in South Africa during the COVID-19 pandemic.

The National Advisory Group on Immunization (NAGI), in South Africa, established in 1993 advises the National Department of Health on issues pertinent to vaccination and infectious diseases. It makes recommendations on vaccine formulations and vaccination schedules.

<span class="mw-page-title-main">Daniela M. Ferreira</span> Brazilian immunologist

Daniela M. Ferreira is a Brazilian British immunologist. She is a specialist in bacterial infection, respiratory co-infection, mucosal immunology and vaccine responses. She is currently Professor of Respiratory Infection and Vaccinology at the Oxford Vaccine Group in the Department of Paediatrics at the University of Oxford and the Director of the Liverpool Vaccine Group at the Liverpool School of Tropical Medicine. She leads a team of scientists studying protective immune responses against pneumococcus and other respiratory pathogens such as SARS-CoV2. Her team has established a novel method of inducing pneumococcal carriage in human volunteers. They use this model to:

<span class="mw-page-title-main">Susanna Dunachie</span> British microbiologist

Susanna Jane Dunachie is a British microbiologist who is Professor of Infectious Diseases at the University of Oxford. Her work considers microbiology and immunology to better understand bacterial infection and accelerate the development of vaccines. She has focused on melioidosis, scrub typhus and tuberculosis. During the COVID-19 pandemic, she studied T cell immunity to severe acute respiratory syndrome coronavirus 2.

Helen Siobhan Marshall is an Australian medical researcher who is Professor of Vaccinology at the University of Adelaide. She was named the South Australian of the Year for 2022.

Cheryl Cohen is a South African public health researcher who is a professor at the University of the Witwatersrand. She looks to develop evidence-based policy to reduce the burdens of respiratory diseases. During the COVID-19 pandemic. Cohen investigated the rates of COVID-19 in South Africa.

Live recombinant vaccines are biological preparations that improve immunity through the use of live bacteria or viruses that are genetically modified. These live pathogens are biologically engineered to express exogenous antigens in the cytoplasm of target cells, triggering immune responses as a result. This form of vaccine combines the beneficial features of attenuated and recombinant vaccines, providing the preparation with attenuated vaccines’ long-lasting immunity and recombinant vaccines’ genetically engineered precision and safety.

References

  1. 1 2 3 Curriculum Vitae: Shabir Madhi. World Association for Infectious Diseases and Immunological Disorders, via www.waidid.
  2. 1 2 3 Saba, Athandiwe (5 September 2020). "Q&A Sessions: The accidental vaccinologist". The Mail & Guardian. Retrieved 7 January 2021.
  3. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 "Immunization, Vaccines and Biologicals: Professor Shabir A. Madhi". World Health Organization. Archived from the original on 15 July 2020. Retrieved 5 January 2021.
  4. "Prof Shabir Madhi" . Retrieved 5 January 2021.
  5. "Shabir A. Madhi". The Conversation. Retrieved 5 January 2021.
  6. "Respiratory and Meningeal Pathogens Reaearch Unit". www.rmpru.com. Archived from the original on 8 February 2021. Retrieved 8 February 2021.
  7. "Director of SAMRC extramural research unit appointed Dean of the Faculty of Health Sciences at Wits University" . Retrieved 8 February 2021.
  8. "Biographies - Wits University". www.wits.ac.za. Retrieved 8 February 2021.
  9. 1 2 Acton, Q. Ashton, ed. (2011). Pneumococcal Disease: New Insights for the Healthcare Professional: 2011 Edition: ScholarlyBrief. Atlanta, Georgia: Scholarly Editions. ISBN   978-1-4649-0303-8.
  10. 1 2 Dunne, Eileen M.; Pilishvili, Tamara; Adegbola, Richard A. (1 December 2020). "Assessing reduced-dose pneumococcal vaccine schedules in South Africa". The Lancet Infectious Diseases. 20 (12): 1355–1357. doi: 10.1016/S1473-3099(20)30577-6 . hdl: 11343/252581 . ISSN   1473-3099. PMID   32857991 . Retrieved 8 January 2021.
  11. "Rotarix™ significantly reduced severe rotavirus gastroenteritis in African babies during their first year of life | GSK". www.gsk.com. Retrieved 17 January 2021.
  12. "Rotavirus vaccine support". www.gavi.org. GAVI. Retrieved 17 January 2021.
  13. Edwards, K. M.; Creech, C. B. (2017). "8. Vaccine development in special populations". In Modjarrad, Kayvon; Koff, Wayne C. (eds.). Human Vaccines: Emerging Technologies in Design and Development. Elsevier. p. 172. ISBN   978-0-12-802302-0.
  14. Harrison, Pam. "Vaccine Reduces Influenza Risk in Mothers and Newborns". Medscape. Retrieved 8 January 2021.
  15. Fox, Steven. "Limited Efficacy Seen for HIV-Related TB Prophylaxis". Medscape. Retrieved 8 January 2021.
  16. Makoni, Munyaradzi (1 November 2020). "COVID-19 vaccine trials in Africa". The Lancet Respiratory Medicine. 8 (11): e79–e80. doi: 10.1016/S2213-2600(20)30401-X . ISSN   2213-2600. PMC   7831818 . PMID   32896275.
  17. Callaway, Ewen; Mallapaty, Smriti (29 January 2021). "Novavax offers first evidence that COVID vaccines protect people against variants". Nature. 590 (7844): 17. doi:10.1038/d41586-021-00268-9. PMID   33510489. S2CID   231760366.
  18. Harding, Andrew (4 January 2021). "Covid-19 in South Africa: Scientists seek to understand new variant". BBC News. Retrieved 8 January 2021.
  19. "South Africa Rolls Out Continent's First Trials for COVID-19 Vaccine". Medscape. 25 June 2020. Retrieved 8 January 2021.
  20. "Trial of Oxford COVID-19 vaccine in South Africa begins | University of Oxford". www.ox.ac.uk. 23 June 2020. Retrieved 12 January 2021.
  21. Pilling, David (28 December 2020). "South Africa battles to control second Covid wave as cases top 1m". www.ft.com. Financial Times. Retrieved 8 January 2021.
  22. Ledford, Heidi (8 December 2020). "Oxford COVID-vaccine paper highlights lingering unknowns about results". Nature. 588 (7838): 378–379. doi:10.1038/d41586-020-03504-w. PMID   33293710.
  23. 1 2 Head, Tom (1 January 2021). "'SA may not get vaccines in 2021': Top virologist criticises Zweli Mkhize". The South African. Retrieved 8 January 2021.
  24. "Professor Shabir Madhi". MPRU. Retrieved 5 January 2021.